FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses

Acta Oncologica

Volumn 54, Issue 6, 2015, Pages 909-915

  Nkhali, Lamyaa ^a   Thureau, Sébastien ^a   Edet Sanson, Agathe ^a   Doyeux, Kaya ^a   Benyoucef, Ahmed ^a   Gardin, Isabelle ^a   Michel, Pierre ^a   Vera, Pierre ^a   Dubray, Bernard ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTINUOUS INFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; RADIATION EXPOSURE; RADIOTHERAPY PLANNING SYSTEM; SPINAL CORD; TREATMENT PLANNING; AGED; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGEAL NEOPLASMS; FEMALE; LUNG; MALE; MIDDLE AGED; MULTIMODAL IMAGING; ORGANS AT RISK; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RADIATION DOSE; RADIOGRAPHY; SCINTISCANNING; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; MALE; MIDDLE AGED; MULTIMODAL IMAGING; ORGANS AT RISK; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SPINAL CORD; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84929315025     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.973062     Document Type: Article

References (25)

1. Pennathur A, Gibson MK, Jobe B A, Luketich J D. O esophageal carcinoma. Lancet 2013; 381: 400-12
2. Pottgen C, Stuschke M. R adiotherapy versus surgery within multimodality protocols for esophageal cancer-a meta-analysis of the randomized trials. Cancer Treat Rev 2012; 38: 599-604
3. Morota M, Gomi K, Kozuka T, Chin K, Matsuura M, Oguchi M,.et al. Late toxicity after defi nitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys 2009; 75: 122-8
4. Minsky BD, Pajak T F, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R,.et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standarddose radiation therapy. J Clin Oncol 2002; 20: 1167-74
5. Hurmuzlu M, v reb K, Wentzel-Larsen T, Muren LP, Viste A, Smaaland R. High-dose preoperative chemoradiotherapy in esophageal cancer patients does not increase postoperative pulmonary complications: Correlation with dose-volume histogram parameters. Radiother Oncol 2010; 97: 60-4
6. Welsh J, Palmer MB, Ajani JA, Liao Z, Swisher SG, Hofstetter WL,.et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 2012; 82: 468-74
7. Lambrecht M, Haustermans K. C linical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. Radiother Oncol 2010; 96: 339-46
8. Palie O, Michel P, Menard J F, Rousseau C, Rio E, Bridji B,.et al. The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). Eur J Nucl Med Mol Imaging 2013; 40: 1345-55
9. Herskovic A, Martz K, al-S arraf M, Leichman L, Brindle J, Vaitkevicius V,.et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. New Engl J Med 1992; 326: 1593-8
10. Lemarignier C, Di Fiore F, Marre C, Hapdey S, Modzelewski R, Dubray B,.et al. Eur J Nucl Med (in press).
11. Chandra A, Guerrero T M, Liu HH, Tucker SL, Liao Z, Wang X,.et al. Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 2005; 77: 247-53
12. Kole TP, Aghayere O, Kwah J, Yorke E D, Goodman K A. Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 83: 1580-6
13. Welsh J, Gomez D, Palmer M B, Riley B A, Mayankkumar AV, Komaki R,.et al. Intensity-modulated proton therapy further reduces normal tissue exposure during defi nitive therapy for locally advanced distal esophageal tumors: A dosimetric study. Int J Radiat Oncol Biol Phys 2011; 81: 1336-42
14. van Westreenen HL, Westerterp M, Bossuyt PM, Pruim J, Sloof GW, van Lanschot JJ,.et al. Systematic review of the staging performance of 18F-fl uorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004; 22: 3805-12
15. Muijs CT, Beukema JC, Pruim J, Mul VE, Groen H, Plukker JT,.et al. A systematic review on the role of FDGPET/CT in tumour delineation and radiotherapy planning in patients with esophageal cancer. Radiother Oncol 2010; 97: 165-71
16. Vrieze O, Haustermans K, De Wever W, Lerut T, Van Cutsem E, Ectors N,.et al. Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma?. Radiother Oncol 2004; 73: 269-75
17. Mamede M, El Fakhri G, Abreu-e-Lima P, Gandler W, Nose V, Gerbaudo VH. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confi rmation. Ann Nucl Med 2007; 21: 553-62
18. Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J, e t al. Comparison of (18)F-fl uorothymidine and (18)F-fl uorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys 2010; 76: 1235-41
19. Edet-Sanson A, Dubray B, Doyeux K, Back A, Hapdey S, Modzelewski R,.et al. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC). Radiother Oncol 2012; 102: 251-7
20. van Hagen P, Hulshof M C, v an Lanschot J J, Steyerberg E W, van Berge Henegouwen MI, Wijnhoven BP,.et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New Engl J Med 2012; 366: 2074-84
21. Kwee RM. P rediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: A systematic review. Radiology 2010; 254: 707-17
22. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T,.et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-8
23. Machtay M, Bae K, Movsas B, Paulus R, Gore EM, Komaki R,.et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: An analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2012; 82: 425-34
24. van Baardwijk A, Bosmans G, Boersma L, Wanders S, Dekker A, Dingemans AM,.et al. Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: A feasibility study. Int J Radiat Oncol Biol Phys 2008; 71: 1394-401
25. Bentzen M S. D ose-response relationships in radiotherapy, In: Basic clinical radiobiology, 4th ed. Joiner M, van der Kogel A, editors. London: CRC Press; 2010. pp 56-66